A visual and narrative timeline of US FDA milestones for Transcranial Magnetic Stimulation (TMS) devices
Year: 2021
Type: article
Abstract: It has been over a decade since the initial US Food and Drug Administration (FDA) approval of Transcranial Magnetic Stimulation (TMS). The technology was first approved for treating Major Depressive Disorder (MDD) in adults who have not responded satisfactorily to prior antidepressant medications in 2008 using the Neuronetics Neurostar System (DEN070003). Since then, refinement and optimization of TMS has paved the way to new and emerging technology that improves and broadens the clinical utility of TMS – such as pulse train protocols (e.g., iTBS and 18/20 Hz stimulation), neuronavigational systems, and electromagnetic coil technology.
Source: Brain stimulation
Language: English
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,310
Awards: kHz frequency Spinal Cord Stimulation: Novel Temperature-Based Mechanisms of Action, "Bridges to the Baccalaureate Research Training Program at LaGuardia Community College", Non-Invasive Vagal Nerve Stimulation in Patients with Opioid Use Disorders, National Center of Neuromodulation for Rehabilitation (NC NM4R), COBRE in Stroke Recovery, Center for Opioid and Cocaine Addiction (COCA), Transcutaneous auricular neurostimulation for neonatal abstinence syndrome, The coupled vascular hypothesis for transcranial direct current stimulation (tDCS), Effects of direct-current stimulation on synaptic plasticity, A tool-box to control and enhance tDCS spatial precision
OpenAlex ID: W3214323141